Related Experiment Video
Updated: Jun 11, 2025
Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
Published on: June 7, 2020
Comprehensive Computational Screening and Analysis of Natural Compounds Reveals Promising Estrogen Receptor Alpha
Perwez Alam1, Pradeep Sharma2, Mohammed Faiz Arshad3
1Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O Box 2457, Riyadh, 11451, Saudi Arabia.
Abstract:
Breast cancer remains a leading cause of death among women, with estrogen receptor alpha (ERα) overexpression playing a pivotal role in tumor growth and progression. This study aimed to identify novel ERα inhibitors from a library of 561 natural compounds using computational techniques, including virtual screening, molecular docking, and molecular dynamics simulations. Four promising candidates - Protopine, Sanguinarine, Pseudocoptisine, and Stylopine - were selected based on their high binding affinities and interactions with key ERα residues. Molecular dynamics simulations conducted over 500 nanoseconds revealed that Protopine and Sanguinarine exhibited more excellent stability with minimal fluctuations, suggesting strong and stable binding. In contrast, Pseudocoptisine and Stylopine showed higher flexibility, indicating less stable interactions. Binding free energy calculations further supported the potential of Protopine and Sanguinarine as ERα inhibitors, though their binding strength was slightly lower than that of the reference compound. These findings highlight Protopine and Sanguinarine as leading candidates for further investigation, and in vitro and in vivo studies are recommended to evaluate their therapeutic potential in breast cancer treatment.
Insights
Researchers identified natural compounds Protopine and Sanguinarine as potential inhibitors of estrogen receptor alpha (ERα) to combat breast cancer. Further studies are needed to confirm their therapeutic efficacy.
Area of Science:
- Oncology
- Pharmacology
- Computational Chemistry
Background:
- Breast cancer is a major cause of mortality in women.
- Estrogen receptor alpha (ERα) overexpression drives tumor growth and progression.
- Targeting ERα is a key strategy in breast cancer treatment.
Purpose of the Study:
- To identify novel ERα inhibitors from a natural compound library.
- To evaluate the binding affinity and stability of potential inhibitors using computational methods.
- To select promising candidates for further preclinical investigation.
Main Methods:
- Virtual screening of 561 natural compounds against ERα.
- Molecular docking to assess binding interactions.
- Molecular dynamics simulations (500 ns) to analyze stability.
- Binding free energy calculations.
Main Results:
- Four compounds (Protopine, Sanguinarine, Pseudocoptisine, Stylopine) showed high binding affinity.
- Protopine and Sanguinarine demonstrated stable binding and minimal fluctuations in simulations.
- Pseudocoptisine and Stylopine exhibited more flexible, less stable interactions.
- Binding free energy calculations supported Protopine and Sanguinarine as potential ERα inhibitors.
Conclusions:
- Protopine and Sanguinarine are promising candidates for ERα inhibition in breast cancer.
- These compounds warrant further in vitro and in vivo evaluation for therapeutic potential.
- Computational approaches are effective for identifying novel drug leads from natural products.
